As an instance, miR-17-5p expression was found to be upregulated in NSCLC cells with bone metastasis, which promotes osteoclastogenesis by targeting the PTEN-activated PI3K/Akt pathway in lung cancer, and treatment with LY 294002, an inhibitor of the PI3K/Akt pathway, inhibited miR-17-5p-mediated osteoclastogenesis (44). Here, PIK3CA is linked to non-small cell lung carcinoma.